Answer questions at the heart of your business, questions that in-house analysis may have left unchallenged.
Evaluate Custom Solutions
Testimonials
“ Evaluate Custom Solutions paid careful attention to our report needs, and the after-care service was excellent, so our level of satisfaction was extremely high. It was one of the best services that I have experienced so far. ”
Motomu Himori, Specialist, Chugai Pharmaceutical Co., Ltd.
“ I really could not do my job without Evaluate data. You guys make me look good all the time. ”
Business Development & Licensing, Large Pharmaceutical
Over the last year, 13 of the world’s largest pharmaceutical and biotech companies have engaged Evaluate Custom Solutions in addressing their biggest global challenges. These clients have engaged us to provide insight to help inform a range of their key objectives including: Market Analysis & Competitor Intelligence, Corporate Strategy & Franchise Planning, Market Expansion & Forecasting, Mergers & Acquisition, New Product Development, Market Access and Pricing & Commercialization.
Below are some examples of the work we have undertaken for the likes of Abbvie, Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Gilead, GSK, Johnson & Johnson/Janssen, Merck KGaA, Novartis, Pfizer, Roche/Chugai and Sanofi.
経営戦略部門向け
事例 - 大手グローバル製薬会社クライアント
市場環境・競合状況・戦略的方向性などについて、第三者視点の製薬市場動向分析を、経営戦略策定会議にて活用されています。
研究開発企画 ＆ ポートフォリオ戦略部門向け
お客様の製品ポートフォリオを客観的に検証するために、第三者機関として当社をご利用いただけます。
事例 - 日本の製薬企業クライアント
研究開発の生産性について、自社と競合他社をベンチマークし潜在的な傾向や成功/失敗要因を把握するために当社サービスを活用しています。
デジタル化 & データサイエンスに関わる部門向け
業界を代表する当社の各種分析データを、データフィードやAPIによってお客様の社内ツール、システム、ワークフローに直接組み込むことも可能です。
事例 - 米国の大手製薬企業クライアント
Ｍ＆Ａ候補スクリーニングツールとして、当社データを組み込んだダッシュボード（データ更新型可視化ツール）を開発し、活用しています。
コマーシャル部門・ファイナンス部門向け
事例 - 中規模製薬会社クライアント
疫学調査、売上予測モデル、薬価分析におけるニーズに合わせた調査分析や、全ての自社製品に標準的に適用できる売上予測モデルの構築によって、製品戦略にお役立ていただいています。
事業開発 & ライセンシング部門向け
事例 – 中規模の製薬企業クライアント
ライセンシング候補となる他社アセットリストを入手し、パートナリング、ライセンスイン、アセット売却に向けた調査・スクリーニング作業の迅速化・効率化を実現しています。
Our services are designed for teams defining product and portfolio strategy and setting direction for key brands and franchises. We provide insight into Market Analysis & Competitor Intelligence, Corporate Strategy & Franchise Planning, Market Expansion & Forecasting, Mergers & Acquisition, New Product Development, Market Access and Pricing & Commercialization.
Leveraging a foundation of extensive Evaluate data augmented with further secondary research, modelling, and analysis, our solutions are data-driven and insight-focused. We also conduct targeted primary research with Key Opinion Leaders, Healthcare Professionals and Payers to validate our assumptions and test our hypotheses.
Below we have provided an overview of our services and how they apply to the life stages of companies / products. If there is something that is not listed here please contact us so we can work with you to get you the insights you need.
Please click on the “+” to read our case studies.
Discovery & Preclinical
Early Clinical Development (P1-P2a)
Late Clinical Development (P2b-P3)
Commercialisation
Market Analysis & Competitive Intelligence
High impact, forward-looking insight into market trends and the drivers fuelling the growth of the industry, providing outside-in perspectives on market evolution and your company’s positioning in the landscape.
Please click the links below for our case studies:
- Insights to provide “outside-in” context to a post-M&A Executive team strategy session
- Analysis to support long-range therapy area strategy review for a major US pharma
- Peer company R&D productivity benchmarking for a major Japanese pharma
- Regular reporting of key competitor developments for a major European pharma
Industry trend & growth driver analysis
Productivity & return on investment benchmarking
Indication landscape & evolution analysis
Competitor strategy profiling
Competitive landscape evolution and outlook
Epidemiology Modelling & Systematic Literature Review
Rigorous research and analysis to construct fully customised and focused fit-for-purpose epidemiology models, designed to underpin market sizing, opportunity assessment, product targeting, and product value measurement.
Please click the links below for our case studies:
Burden of illness & incidence/prevalence studies
Global/regional/country-specific patient segmentation modelling
Standard of care & treatment paradigm definition
Clinical outcomes & treatment pattern studies
Market sizing & unmet need identification
Oncology patient dynamic flow modelling
Rare disease epidemiology
Opportunity Identification & Quantification
Robust comparative assessments leveraging unique Evaluate metrics and incorporating scientific, clinical, and commercial drivers, providing insights to guide informed portfolio strategy and prioritisation decision making.
Please click the links below for our case studies:
- Supporting licensing target identification and prioritisation for a mid-sized Canadian pharma
- Insights into global technology research trends to support strategic review for a major Japanese pharma
- Analysis of evolving unmet clinical needs and competitor activity for a major Japanese pharma
- Asset due diligence and sales forecast development to support investment thesis validation for a major global life sciences investor
Market profiling & segment analysis
Indication sizing, scoring & prioritisation
Competitive intensity analysis
Market opportunity analysis & forecasting
Opportunity identification, fit & prioritisation assessment
BD&L target search, screen & assessment
Partner identification & profiling
Deal benchmarking analysis
Product Strategy & Differentiation
Deep analysis of product differentiators and value in the context of an ever evolving and dynamic market, providing objective perspectives to influence product targeting and strategy in support of development planning, fund-raising, and deal-making.
Please click the links below for our case studies:
- Supporting early pipeline program target indication selection for a mid-sized Japanese pharma
- Analysis of lead asset optimal development pathway and commercial potential for a US biotech
- Pan-tumour portfolio asset valuation for early phase US biotech
- Epidemiology & patient-based in-depth global forecast models for oncology and rare-disease areas
- Product pricing analysis across multiple countries for multiple price points
Niche identification & addressable population sizing
Product positioning & differentiation assessment
Target product profile (TPP) definition & testing
Price benchmarking & sensitivity analysis
Scenario-based sales & volume forecast modelling
Product targeting & development strategy assessment
Data Feeds & APIs
Programmatic access to Evaluate data
Resources
Oncology Market Forecasting
Most analysts can find forecasting in oncology daunting as it is a highly specialised and technical area, mixed with plenty of seemingly impenetrable terms. This document addresses these nuances and breaks them down so they can be digested more easily to help readers fully optimize their forecasting.
An introduction to Custom Solutions
Our unmatched combination of industry renowned forecasts, proprietary methodologies and ubiquitous products along with our highly qualified, multi-disciplined experts; uniquely positions us as the only choice when you need cost-effective, deeply analytical, data-driven insight. Please download to find out more.
Establishing Rare Disease Prevalence
Largely driven by the payer environment, the focus of drug development has shifted in the last 10 years to rare diseases. Due to the lack of solid epidemiology data available, over 7,000 rare diseases (many being sub-sets of larger diseases), have not been quantified, posing a problem when using prevalent population estimates to create forecasts. This document discusses the challenges in determining accurate patient population estimates for rare diseases and the best practice methodologies to arrive at appropriate prevalent and incident population figures.
Asset valuations in Healthcare
Healthcare is a heavily specialist arena and it is not always easy to understand what a quality valuation should be based on and include. Accurate consideration of true drivers of the market is both an art and a science. This document breaks the valuation down in to its constituent income and expenditure parts and discusses the level of detail that is expected.